Literature DB >> 27820930

Is There Benefit from Stenting on Cognitive Function in Intracranial Atherosclerosis?

Tanya N Turan1, Alison Smock, George Cotsonis, David Bachman, Sami Al Kasab, Michael J Lynn, Azhar Nizham, Collin P Derdeyn, David Fiorella, Scott Janis, Bethany Lane, Jean Montgomery, Marc I Chimowitz.   

Abstract

BACKGROUND: Revascularization of stenotic cerebral arteries is hypothesized to improve cognition by increasing cerebral perfusion. AIMS: We compared cognition impairment among patients treated with percutaneous angioplasty and stenting (PTAS) and aggressive medical management (AMM) versus AMM alone in the Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis (SAMMPRIS) Trial.
METHODS: In SAMMPRIS, 451 patients with recent transient ischemic attack or stroke attributed to 70-99% intracranial stenosis were randomized to PTAS plus AMM or AMM alone. Patients who had stroke as the qualifying event with National Institutes of Health Stroke Scale indicating aphasia or neglect were excluded from these analyses. Patients with a cerebrovascular event (ischemic stroke, cerebral infarct with temporary signs or intracranial hemorrhage) during follow-up were excluded from follow-up visit analyses. The Montreal Cognitive Assessment (MoCA) score was used to assess cognition impairment at baseline, 4 months, 12 months and closeout. Cognitive impairment was defined as MoCA <26. Mean MoCA scores and the percentage of patients with cognitive impairment were compared between treatment groups at each time point using t tests and chi-square tests. Differences in MoCA mean at baseline and follow-up time points were compared using mixed model repeated measures ANOVA and Tukey-Kramer tests.
RESULTS: There were no significant differences between the treatment groups for mean MoCA at any time point. Mean MoCA scores improved in both groups. The percentage of patients with cognitive impairment in the AMM versus PTAS groups was not significantly different at any time point.
CONCLUSIONS: Revascularization with PTAS showed no improvement in cognitive impairment over AMM alone among patients who did not have recurrent cerebrovascular events during follow-up.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27820930      PMCID: PMC5319918          DOI: 10.1159/000450964

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  10 in total

1.  The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.

Authors:  Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow
Journal:  J Am Geriatr Soc       Date:  2005-04       Impact factor: 5.562

2.  Design of the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis trial.

Authors:  Marc I Chimowitz; Michael J Lynn; Tanya N Turan; David Fiorella; Bethany F Lane; Scott Janis; Colin P Derdeyn
Journal:  J Stroke Cerebrovasc Dis       Date:  2011 Jul-Aug       Impact factor: 2.136

3.  Rationale, design, and implementation of aggressive risk factor management in the Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial.

Authors:  Tanya N Turan; Michael J Lynn; Azhar Nizam; Bethany Lane; Brent M Egan; Ngoc-Anh Le; Maria F Lopes-Virella; Kathie L Hermayer; Oscar Benavente; Carole L White; W Virgil Brown; Michelle F Caskey; Meghan R Steiner; Nicole Vilardo; Andrew Stufflebean; Colin P Derdeyn; David Fiorella; Scott Janis; Marc I Chimowitz
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-09-01

4.  Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Walter N Kernan; Bruce Ovbiagele; Henry R Black; Dawn M Bravata; Marc I Chimowitz; Michael D Ezekowitz; Margaret C Fang; Marc Fisher; Karen L Furie; Donald V Heck; S Claiborne Clay Johnston; Scott E Kasner; Steven J Kittner; Pamela H Mitchell; Michael W Rich; DeJuran Richardson; Lee H Schwamm; John A Wilson
Journal:  Stroke       Date:  2014-05-01       Impact factor: 7.914

5.  Low mini-mental status predicts mortality in asymptomatic carotid arterial stenosis. Asymptomatic Carotid Atherosclerosis Study investigators.

Authors:  L C Pettigrew; N Thomas; V J Howard; R Veltkamp; J F Toole
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

6.  Mild cognitive impairment in symptomatic and asymptomatic cerebrovascular disease.

Authors:  Irena Martinić Popović; Vesna Serić; Vida Demarin
Journal:  J Neurol Sci       Date:  2007-02-27       Impact factor: 3.181

7.  A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.

Authors:  Tiia Ngandu; Jenni Lehtisalo; Alina Solomon; Esko Levälahti; Satu Ahtiluoto; Riitta Antikainen; Lars Bäckman; Tuomo Hänninen; Antti Jula; Tiina Laatikainen; Jaana Lindström; Francesca Mangialasche; Teemu Paajanen; Satu Pajala; Markku Peltonen; Rainer Rauramaa; Anna Stigsdotter-Neely; Timo Strandberg; Jaakko Tuomilehto; Hilkka Soininen; Miia Kivipelto
Journal:  Lancet       Date:  2015-03-12       Impact factor: 79.321

8.  Randomized Evaluation of Carotid Occlusion and Neurocognition (RECON) trial: main results.

Authors:  Randolph S Marshall; Joanne R Festa; Ying-Kuen Cheung; Marykay A Pavol; Colin P Derdeyn; William R Clarke; Tom O Videen; Robert L Grubb; Kevin Slane; William J Powers; Ronald M Lazar
Journal:  Neurology       Date:  2014-01-29       Impact factor: 9.910

9.  Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.

Authors:  Colin P Derdeyn; Marc I Chimowitz; Michael J Lynn; David Fiorella; Tanya N Turan; L Scott Janis; Jean Montgomery; Azhar Nizam; Bethany F Lane; Helmi L Lutsep; Stanley L Barnwell; Michael F Waters; Brian L Hoh; J Maurice Hourihane; Elad I Levy; Andrei V Alexandrov; Mark R Harrigan; David Chiu; Richard P Klucznik; Joni M Clark; Cameron G McDougall; Mark D Johnson; G Lee Pride; John R Lynch; Osama O Zaidat; Zoran Rumboldt; Harry J Cloft
Journal:  Lancet       Date:  2013-10-26       Impact factor: 79.321

10.  Neuropsychological consequences of endarterectomy and endovascular angioplasty with stent placement for treatment of symptomatic carotid stenosis: a prospective randomised study.

Authors:  Karsten Witt; Katharina Börsch; Christine Daniels; Knut Walluscheck; Karsten Alfke; Olav Jansen; Norbert Czech; Günther Deuschl; Robert Stingele
Journal:  J Neurol       Date:  2007-07-31       Impact factor: 6.682

  10 in total
  4 in total

Review 1.  Intracranial atherosclerotic disease.

Authors:  Yuan Wang; Ran Meng; Gang Liu; Catherine Cao; Fenghua Chen; Kunlin Jin; Xunming Ji; Guodong Cao
Journal:  Neurobiol Dis       Date:  2018-11-12       Impact factor: 5.996

2.  Predicting Decreased Activities of Daily Living in Patients with Moyamoya Disease after Revascularization: Development and Assessment of a New Predictive Nomogram.

Authors:  Yani Zhao; Dongliang Yang; Gang Li; Peng Zhao; Xiaorong Luan; Haiyan Li
Journal:  Biomed Res Int       Date:  2021-04-05       Impact factor: 3.411

3.  Poststroke Montreal Cognitive Assessment and Recurrent Stroke in Patients With Symptomatic Intracranial Atherosclerosis.

Authors:  Shadi Yaghi; George Cotsonis; Adam de Havenon; Shyam Prahbakaran; Jose G Romano; Ronald M Lazar; Randolph S Marshall; Edward Feldmann; David S Liebeskind
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-02-07       Impact factor: 2.136

4.  Progression in Vascular Cognitive Impairment: Pathogenesis, Neuroimaging Evaluation, and Treatment.

Authors:  Xin Zhang; Jiabin Su; Chao Gao; Wei Ni; Xinjie Gao; Yuxin Li; Jun Zhang; Yu Lei; Yuxiang Gu
Journal:  Cell Transplant       Date:  2018-11-29       Impact factor: 4.139

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.